Dementia Associated with Alzheimer's Disease Market

Dementia Associated with Alzheimer's Disease Market (Drug Class: Cholinergic/Cholinesterase Inhibitors, Memantine, Combined Drugs, Others; Distribution Channel: Hospital Pharmacies, Retail, Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2023-2031

Global Dementia Associated with Alzheimer's Disease Market Outlook 2031

  • The industry was valued at US$ 6.2 Bn in 2022
  • It is estimated to grow at a CAGR of 4.6% from 2023 to 2031 and reach US$ 9.3 Bn by the end of 2031

Analyst Viewpoint

Surge in prevalence of Alzheimer’s among geriatric population and growth in investments in healthcare facilities are fueling the dementia associated with Alzheimer’s disease market size. Dementia progresses over time among the aging population, and Alzheimer’s and Parkinson’s being its major cause require proper treatments and therapies. Growth in geriatric population across the globe is driving the prevalence of Alzheimer’s and Parkinson’s diseases, thereby fostering market expansion.

Increase in adoption of gene therapy and biomarkers is likely to offer lucrative dementia associated with Alzheimer’s disease market opportunities to leading market players. They are focusing on innovative drug development and conducting clinical trials to seek drug approvals. These strategies are expected to enable drug manufacturers to enhance their product portfolio and improve business performance by providing precise dementia treatments.

Dementia Associated With Alzheimer's Disease Market

Market Introduction

Alzheimer's disease is the most common type of dementia. Dementia is a progressive disease beginning with mild memory loss and possibly leading to loss of control of memory, language, and thought. Lack of functioning of brain proteins, called neurons, is one of the major causes of Alzheimer’s-related dementia. Neurodegenerative disorders caused by Alzheimer’s and Parkinson’s disease are a major concern among the population.

Neuropathological changes in the cerebral cortex and limbic system lead to deficit in learning, memory, language, and visuospatial skills, leading to Alzheimer's-induced cognitive impairment. Loss of spontaneity, taking longer to complete daily tasks, losing track of dates and locations, and forgetting or repeating questions are some of the common symptoms of dementia. Dementia associated with Alzheimer's disease can be treated using memantine, an N-Methyl-D-Aspartate (NMDA) antagonist.

Rise in Prevalence of Alzheimer’s among Geriatric Population Augmenting Market Development

Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects geriatric population and the prevalence of dementia tends to increase with age. Vascular dementia, Lewy body dementia, and frontotemporal dementia are caused due to Alzheimer’s. Growth in geriatric population across the globe is leading to an increase in prevalence of dementia associated with Alzheimer's disease. This, in turn, is driving dementia associated with Alzheimer’s disease industry growth.

According to the World Health Organization, in 2020, the number of people aged 60 years and older outnumbered children younger than 5 years. Between 2015 and 2050, the proportion of the world's population over 60 years is expected to nearly double from 12% to 22%.

Developments in healthcare facilities across the globe are fueling the availability of treatments and therapies for these diseases. Emerging therapies for Alzheimer's-related dementia treatment are likely to boost lucrative dementia associated with Alzheimer’s disease market dynamics in the near future. For instance, in September 2022, the WHO stated that about 55 million people worldwide are living with dementia, and nearly 10 million cases are reported annually. WHO also stated that Alzheimer's is the most common form of dementia and constitutes about 60-70% of the total cases of dementia.

Growth in Investments in Healthcare Facilities Fostering Dementia Associated with Alzheimer's Disease Market Growth

Healthcare professionals focus on reducing the risk associated with drugs for Alzheimer’s disease by adopting advanced precision medicine. These medicines include biomarkers and gene therapy for the treatment of dementia associated with Alzheimer’s disease. Emergence of digital therapeutics and artificial intelligence in Alzheimer's research are major market trends in diagnostic tools for Alzheimer's-associated dementia. An increase in use of biomarkers and imaging techniques for the diagnosis and management of Alzheimer's disease enables physicians to provide efficient and precise treatments. Thus, surge in investments in healthcare facilities is bolstering lucrative dementia associated with Alzheimer’s disease market statistics.

Technological advancements in the drug development sector enable manufacturers to introduce innovative medicine according to disease severity and causes. Advancements in neuroscience research and development of novel therapeutic approaches are boosting market progress. Drug development organizations are conducting multiple clinical trials to record impact and side-effects of the drugs. Hence, introduction of new therapies and treatments is likely to offer lucrative dementia associated with Alzheimer’s disease business opportunities in the next few years.

Regional Outlook

As per the latest dementia associated with Alzheimer’s disease industry analysis, North America dominated the global market in 2022. Rise in aging population and availability of advanced medical facilities are some of the crucial factors projected to propel dementia associated with Alzheimer’s disease market share during the forecast period. Moreover, surge in prevalence of dementia and increase in investments in research and development of dementia therapies are boosting market revenue in the region.

According to the Journal of the Alzheimer’s Association, in the U.S., around 1 in 9 people, which comprises 10.7% of the people aged 65 and older, have dementia due to Alzheimer’s. Approximately 5.0% of the population aged 65 to 74, 13.1% of the population aged 75 to 84, and 33.2% of the population aged 85 and older, have Alzheimer’s dementia.

Analysis of Key Players in Dementia Associated with Alzheimer's Disease Industry

Leading players in the lucrative dementia associated with Alzheimer’s disease market are investing heavily in drug development by conducting in-depth research on the causes, symptoms, and severity of the diseases. They are focusing on providing precise and advanced treatments to ensure efficient results and cater to consumer demands. Prominent players are launching new products and conducting clinical trials to seek approvals from government organizations, thereby enhancing their product portfolio.

Some of the key players in the industry are Merz Pharma, Novartis AG, AbbVie Inc., Pfizer, Inc., Daiichi Sankyo Company, Limited., Ono Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, and F. Hoffmann-La Roche Ltd.

These companies have been profiled in the dementia associated with Alzheimer’s disease market report based on various parameters including company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.

Key Developments

  • In October 2022, Cyclo Therapeutics, Inc., a leading clinical-stage biotechnology company, announced the commencement of its Phase 2b study of Trappsol Cyclo for the treatment of Alzheimer's disease, targeting the reduction of amyloid beta and tau. The Phase 2b study received an Institutional Review Board (IRB) approval.
  • In September 2022, Eisai Co., Ltd., a renowned pharmaceutical company based in Japan, and Biogen Inc., a leading biotechnology company, reported positive topline results from Eisai's sizeable global Phase 3 confirmatory Clarity AD clinical trial of lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of Mild Cognitive Impairment (MCI) due to Alzheimer's disease and mild Alzheimer's disease.

Dementia Associated with Alzheimer's Disease Market Snapshot

Attribute Detail
Market Size in 2022 US$ 6.2 Bn
Market Forecast (Value) in 2031 US$ 9.3 Bn
Growth Rate (CAGR) 4.6%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Tons US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Drug Class
    • Cholinergic/Cholinesterase (ChE) Inhibitors
    • Memantine
    • Combined Drugs (Memantine & Donepezil)
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail
    • Online Sales
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC countries
Companies Profiled
  • Merz Pharma
  • Novartis AG
  • AbbVie Inc.
  • Pfizer, Inc.
  • Daiichi Sankyo Company, Limited.
  • Ono Pharmaceutical Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Eisai Co., Ltd.
  • H. Lundbeck A/S
  • F. Hoffmann-La Roche Ltd.
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global dementia associated with Alzheimer’s disease market in 2022?

It was valued at US$ 6.2 Bn in 2022

How is the dementia associated with Alzheimer’s disease industry expected to grow by 2031?

It is projected to register a CAGR of 4.6% from 2023 to 2031

What are the key factors driving the demand for drugs to treat dementia associated with Alzheimer’s disease?

Rise in prevalence of Alzheimer's among geriatric population and growth in investments in healthcare facilities

Which was the most lucrative region in the dementia associated with Alzheimer’s disease business in 2022?

North America was the most lucrative region in 2022

Who are the prominent players in the dementia associated with Alzheimer’s disease sector?

Merz Pharma, Novartis AG, AbbVie Inc., Pfizer, Inc., Daiichi Sankyo Company, Limited., Ono Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, and F. Hoffmann-La Roche Ltd.

    1. Executive Summary

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Dementia Associated with Alzheimer’s Disease Market

    4. Market Overview

        4.1. Market Segmentation

            4.1.1. Segment Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecasts, 2017-2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Disease Prevalence & Incidence Rate Globally With Key Countries

        5.3. COVID-19 Pandemic Impact on Industry

    6. Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Drug Class

        6.1. Introduction and Definitions

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Drug Class, 2017–2031

            6.3.1. Cholinergic/Cholinesterase (ChE) Inhibitors

            6.3.2. Memantine

            6.3.3. Combined Drugs (Memantine & Donepezil)

            6.3.4. Others

        6.4. Market Attractiveness, by Drug Class

    7. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Distribution Channel

        7.1. Introduction and Definitions

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Distribution Channel, 2017–2031

            7.3.1. Hospital Pharmacies

            7.3.2. Retail

            7.3.3. Online Sales

        7.4. Market Attractiveness, by Distribution Channel

    8. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region, 2017–2031

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness, by Region

    9. North America Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Drug Class, 2017–2031

            9.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors

            9.2.2. Memantine

            9.2.3. Combined Drugs (Memantine & Donepezil)

            9.2.4. Others

        9.3. Market Value Forecast, by Distribution Channel, 2017–2031

            9.3.1. Hospital Pharmacies

            9.3.2. Retail

            9.3.3. Online Sales

        9.4. Market Value Forecast, by Country, 2017–2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

            9.5.1. By Drug Class

            9.5.2. By Distribution Channel

            9.5.3. By Country

    10. Europe Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Drug Class, 2017–2031

            10.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors

            10.2.2. Memantine

            10.2.3. Combined Drugs (Memantine & Donepezil)

            10.2.4. Others

        10.3. Market Value Forecast, by Distribution Channel, 2017–2031

            10.3.1. Hospital Pharmacies

            10.3.2. Retail

            10.3.3. Online Sales

        10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Italy

            10.4.5. Spain

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

            10.5.1. By Drug Class

            10.5.2. By Distribution Channel

            10.5.3. By Country/Sub-region

    11. Asia Pacific Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Drug Class, 2017–2031

            11.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors

            11.2.2. Memantine

            11.2.3. Combined Drugs (Memantine & Donepezil)

            11.2.4. Others

        11.3. Market Value Forecast, by Distribution Channel, 2017–2031

            11.3.1. Hospital Pharmacies

            11.3.2. Retail

            11.3.3. Online Sales

        11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Drug Class

            11.5.2. By Distribution Channel

            11.5.3. By Country/Sub-region

    12. Latin America Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Drug Class, 2017–2031

            12.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors

            12.2.2. Memantine

            12.2.3. Combined Drugs (Memantine & Donepezil)

            12.2.4. Others

        12.3. Market Value Forecast, by Distribution Channel, 2017–2031

            12.3.1. Hospital Pharmacies

            12.3.2. Retail

            12.3.3. Online Sales

        12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Market Attractiveness Analysis

            12.5.1. By Drug Class

            12.5.2. By Distribution Channel

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Drug Class, 2017–2031

            13.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors

            13.2.2. Memantine

            13.2.3. Combined Drugs (Memantine & Donepezil)

            13.2.4. Others

        13.3. Market Value Forecast, by Distribution Channel, 2017–2031

            13.3.1. Hospital Pharmacies

            13.3.2. Retail

            13.3.3. Online Sales

        13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Market Attractiveness Analysis

            13.5.1. By Drug Class

            13.5.2. By Distribution Channel

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player – Competition Matrix (By Tier and Size of Companies)

        14.2. Market Share Analysis, by Company (2022)

        14.3. Company Profiles

            14.3.1. Merz Pharma

                14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.1.2. Product Portfolio

                14.3.1.3. Financial Overview

                14.3.1.4. SWOT Analysis

                14.3.1.5. Strategic Overview

            14.3.2. Novartis AG

                14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.2.2. Product Portfolio

                14.3.2.3. Financial Overview

                14.3.2.4. SWOT Analysis

                14.3.2.5. Strategic Overview

            14.3.3. AbbVie Inc.

                14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.3.2. Product Portfolio

                14.3.3.3. Financial Overview

                14.3.3.4. SWOT Analysis

                14.3.3.5. Strategic Overview

            14.3.4. Pfizer, Inc.

                14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.4.2. Product Portfolio

                14.3.4.3. Financial Overview

                14.3.4.4. SWOT Analysis

                14.3.4.5. Strategic Overview

            14.3.5. Daiichi Sankyo Company, Limited.

                14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.5.2. Product Portfolio

                14.3.5.3. Financial Overview

                14.3.5.4. SWOT Analysis

                14.3.5.5. Strategic Overview

            14.3.6. Ono Pharmaceutical Co., Ltd.

                14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.6.2. Product Portfolio

                14.3.6.3. Financial Overview

                14.3.6.4. SWOT Analysis

                14.3.6.5. Strategic Overview

            14.3.7. Johnson & Johnson Services, Inc.

                14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.7.2. Product Portfolio

                14.3.7.3. Financial Overview

                14.3.7.4. SWOT Analysis

                14.3.7.5. Strategic Overview

            14.3.8. Eisai Co., Ltd.

                14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.8.2. Product Portfolio

                14.3.8.3. Financial Overview

                14.3.8.4. SWOT Analysis

                14.3.8.5. Strategic Overview

            14.3.9. H. Lundbeck A/S

                14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.9.2. Product Portfolio

                14.3.9.3. Financial Overview

                14.3.9.4. SWOT Analysis

                14.3.9.5. Strategic Overview

            14.3.10. F. Hoffmann-La Roche Ltd.

                14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.10.2. Product Portfolio

                14.3.10.3. Financial Overview

                14.3.10.4. SWOT Analysis

                14.3.10.5. Strategic Overview

    List of Tables

    Table 1: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 2: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 3: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 4: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 5: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 6: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 7: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 8: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 9: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031

    Table 10: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 11: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 12: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 13: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 15: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031

    Table 16: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 18: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031

    List of Figures

    Figure 1: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031

    Figure 2: Global Dementia Associated with Alzheimer’s Disease Market Value Share, by Drug Class, 2022

    Figure 3: Global Dementia Associated with Alzheimer’s Disease Market Value Share, by Distribution Channel, 2022

    Figure 4: Global Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 5: Global Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 6: Global Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 7: Global Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031

    Figure 8: Global Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Region, 2022 and 2031

    Figure 9: Global Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Region, 2023–2031

    Figure 10: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031

    Figure 11: North America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country, 2022 and 2031

    Figure 12: North America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country, 2023–2031

    Figure 13: North America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 14: North America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 15: North America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 16: North America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031

    Figure 17: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031

    Figure 18: Europe Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 19: Europe Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 20: Europe Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 21: Europe Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 22: Europe Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 23: Europe Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031

    Figure 24: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031

    Figure 25: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 26: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 27: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 28: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 29: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 30: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031

    Figure 31: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031

    Figure 32: Latin America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 33: Latin America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 34: Latin America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 35: Latin America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 36: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 37: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 38: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 39: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 40: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 41: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031

    Figure 42: Global Dementia Associated with Alzheimer’s Disease Market Share Analysis, by Company (2022)

Copyright © Transparency Market Research, Inc. All Rights reserved